14
Participants
Start Date
August 2, 2022
Primary Completion Date
January 1, 2026
Study Completion Date
July 1, 2027
Canakinumab
Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
RECRUITING
Ruttenberg Treatment Center, New York
RECRUITING
Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem
NOT_YET_RECRUITING
Atrium Health Levine Cancer Institute, Charlotte
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Cleveland Clinic Foundation, Cleveland
RECRUITING
The University of Kansas Cancer Center-Westwood, Westwood
WITHDRAWN
Mayo Clinic Arizona, Phoenix
RECRUITING
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
John Mascarenhas
OTHER